| Name | Title | Contact Details |
|---|---|---|
Hunter Veal |
VP of Payor Contracting | Profile |
Trisura Guarantee Insurance Company, founded in 2006, is a specialty insurance provider focused on delivering tailored insurance and surety solutions in Canada and the United States. As part of Trisura Group Ltd., the company offers expertise in surety, corporate insurance, warranty, program, and fronting business lines. Trisura aims to simplify insurance for its clients by providing personalized and flexible solutions through a select network of brokers. The company offers a wide range of products, including surety bonds, corporate insurance, casualty insurance, cyber insurance, and specialized warranty and program insurance. Trisura primarily serves corporate clients, including small and medium-sized businesses, addressing their unique insurance needs. With a commitment to exceptional service and community involvement, Trisura allocates a portion of its net underwriting income to charitable causes and engages employees in its giving strategy. The company continues to grow, employing over 150 people and expanding its operations in North America.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.